← boardnext 2026-08-30
MSLE
Satellos Bioscience, Inc.distress 0/10 · well-funded / low risk$9.730%today-25% from 52w high
Lead: Duchenne Muscular Dystrophy · est. market ~$4B (approx, global)
Revenue
pre-revenue
Liquidity
$70M
Runway
3.0 yrs
Shares 1y
—
Price & events
+4.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
+11.1%
1W
+71.7%
1M
+43.0%
3M
-5.7%
6M
+93.2%
1Y
+125.3%
2Y
-48.0%
5Y
-20.5%
All
Overview
- Market Cap
- $150.49M
- Volume
- 40.02K
- 52 Week Range
- $4.64 – $13.01
- Total Shares
- 15.46M
- Float Shares
- 17.63M
- % Held by Insiders
- 6.48%
- % Held by Institutions
- 50.62%
- RVOL
- 0.50x
- Beta
- 1.17
Pipeline stages · 1 programs
SAT-3247
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-30 Estimated 50% readout ~2026-10-14 | Phase 2 | SAT-3247 | Duchenne Muscular Dystrophy (DMD) | — | enrolling by invitation |
| 2027-03-31 Estimated 50% readout ~2027-05-15 | Phase 2 | SAT-3247 | Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies | — | recruiting |
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 15,458,903 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $28 (+184% upside) · 3 analysts
- 2026-07-09HC Wainwright & Co.Buy
- 2026-05-18HC Wainwright & Co.Buy
- 2026-04-28GuggenheimBuy
- 2026-04-06Leerink PartnersOutperform
- 2026-03-30HC Wainwright & Co.Buy
- 2026-03-11Cantor FitzgeraldOverweight
Competitors — Duchenne Muscular Dystrophy
- EWTXEdgewise Therapeutics, Inc.$4.1B · D4
- DYNDyne Therapeutics, Inc.$3.3B · D4
- SRPTSarepta Therapeutics, Inc.$1.6B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CAPRCAPRICOR THERAPEUTICS, INC.$1.1B · D4
- SLDBSolid Biosciences Inc.$777M · D4
- RGNXREGENXBIO Inc.$508M · D7
- TRDAEntrada Therapeutics, Inc.$236M · D2
- DTILPRECISION BIOSCIENCES INC$185M · D6
- PEPGPepGen Inc.$133M · D6
Recent news
- 2026-07-23Why Satellos Bioscience Inc. stock surged yesterday - Wealth Awesome
- 2026-07-22What's Going On With Satellos Bioscience Inc. Stock Wednesday? - Wealth Awesome
- 2026-07-21Why Satellos Bioscience Inc. stock fell yesterday - Wealth Awesome
- 2026-07-20Why Satellos Bioscience Inc. stock is plummeting today - Wealth Awesome
- 2026-07-20Independent Director of Satellos Bioscience Picks Up 1.9% More Stock - simplywall.st
- 2026-07-17Satellos Bioscience Inc. (MSLE) Q1 2026 Earnings: Wider-Than-Expected Loss Reflects R&D Spending; Stock Rises Despite EPS Miss - Gross Profit Margin - dars.gov.et
- 2026-07-17Why Satellos Bioscience Inc. stock is sliding today - Wealth Awesome
- 2026-07-16What's Going On With Satellos Bioscience Inc. Stock Thursday? - Wealth Awesome
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.